Tip os
Log ind
Peter Mørch Eriksen.jpg
Foto: BioPorto PR

Increased US activity led to management change in Bioporto

Top picks in English:

Increased activity on the US market is the reason for a change of guards at the helm of the Danish diagnostics group Bioporto’s operations.


BY ANTON GRÆSDAL MAAJEN
Offentliggjort 10.08.16 kl. 11:43

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Here is what Danish drug companies pay their workers

Løn Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Novo will no longer offer price guidance

Top picks in English:

Novo Nordisk will no longer announce the expected price development for its products on the US market.

ALK CEO: We call the FDA on a daily basis

Top picks in English:

Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.

Zealand carries out USD 89m IPO in the US

Top picks in English:

Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.

Novo Holdings invests in Canadian company

Top picks in English:

Once again, Novo Holdings has led a sizeable investment round in North America. The company gets a position on the board of the new portfolio company, which develops a nasal spray against atrial fibrillation.

Novo expands its executive team

Top picks in English:

Novo Nordisk has promoted two of its regional directors to its executive management team, which has undergone a slew of changes in the past year.

Forsiden lige nu

Novo Nordisks store håb overgår ærkerivalen

Novo Nordisk flag-version2.jpg Medicinal & Biotek:

Novo Nordisks ugentlige GLP-1-analog semaglutid har vist sig mere effektiv end det lignende produkt Trulicity fra ærkerivalen Eli Lilly i et klinisk studie.

Veloxis nedjusterer forventninger trods fremgang over hele linjen

Medicinal & Biotek:

De første seks måneder af året har budt på fremgang på top- og bundlinje hos biotekselskabet Veloxis Pharmaceuticals.

Krænkelse af Coloplast-patent får betydelige konsekvenser

Medico & Rehab:

Der trækker op til en større erstatningsrunde til Coloplast, efter selskabet har vundet to patentsager i løbet af sommeren, lyder det fra selskabets adm. direktør Lars Rasmussen.

Medicinrådet mangler formænd til kræftråd

Medicinal & Biotek:

Fire fagudvalg under Danske Regioners Medicinråd står uden formand, da det er svært at finde egnede kandidater, der lever op til rådets habilitetsregler.

Coloplast-direktør: Kina er kommet op i gear

Medico & Rehab:

Der har været godt gang i Coloplasts kinesiske forretning i tredje kvartal, hvor året ellers startede med negativ vækst i selskabets sårplejedivision. Den positive udvikling fortsætter ind i fjerde kvartal, vurderer selskabets finansdirektør Anders Lonning-Skovgaard.

Sydbank: Sårpleje er synderen i Coloplast-regnskab

Medico & Rehab:

Kvartalsregnskabet for medicokoncernen Coloplast har vist sig svagere, end analytikernes forventninger, og det skyldes først og fremmest stomiporteføljen samt hud- og sårpleje.

ANNONCE
ANNONCE


ANNONCE